Study Information
Study Details
View study details on clinicaltrials.gov.
Locations
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects With Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma.
Location: REDI (East Bay)
Please contact Vivian Leong LeongV@sutterhealth.org about MAGNIFY
Principal Investigator
Recruitment Information
Please note that trial statuses change frequently, for the most up to date information regarding REDI's enrolling studies; please contact the research department at 510-204-5571.
Funder
Celgene Corporation